La bourse ferme dans 2 h 38 min

Sanofi (SNY)

NasdaqGS - NasdaqGS Cours en temps réel. Devise en USD
Ajouter à la liste dynamique
51,20+0,77 (+1,53 %)
À la clôture : 04:00PM EDT
52,72 +1,52 (+2,97 %)
Avant Bourse : 08:52AM EDT


46, avenue de la Grande Armée,
Paris 75017
33 1 53 77 40 00

Secteur d’activitéDrug Manufacturers - General
Employés à temps plein86 088

Dirigeants clés

NomTitrePayerExercéAnnée de naissance
Mr. Paul HudsonCEO & Director4,11MS.O.1967
Mr. François-Xavier RogerExecutive VP & CFOS.O.S.O.1962
Ms. Madeleine RoachExecutive VP & Head of Business OperationsS.O.S.O.1984
Mr. Laurent GilhodesPrincipal Accounting Officer and Vice President of Corporate AccountingS.O.S.O.S.O.
Dr. Josephine FubaraChief Science Officer of Consumer Health CareS.O.S.O.S.O.
Mr. Thomas Kudsk LarsenHead of Investor RelationsS.O.S.O.1974
Mr. Dante BeccariaGlobal Compliance Officer & VPS.O.S.O.S.O.
Mr. Roy PapatheodorouExecutive VP & General CounselS.O.S.O.1978
Mr. Josep CatllaHead of CommunicationsS.O.S.O.S.O.
Mr. Pierre ChancelSenior Vice President of Global Diabetes and Senior Vice President of Global MarketingS.O.S.O.1957
Les montants ont été établis en date du 31 décembre 2023 et les valeurs de compensation concernent le dernier exercice fiscal clos à cette date. Le terme « rémunération » désigne le salaire, les bonus, etc. Le terme « exercé » est utilisé pour la valeur des options exercées au cours de l’exercice fiscal. Devise exprimée en USD.


Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Gouvernance d’entreprise

L’ISS Governance QualityScore de Sanofi en date du 1 juillet 2024 est 2. Les scores principaux sont Audit : 4; Société : 2; Droits des actionnaires : 5; Compensation : 2.

Résultats de gouvernance d’entreprise offerts par Institutional Shareholder Services (ISS). Les résultats indiquent un rang décile par rapport à l’indice ou à la région. Un résultat décile de 1 indique un risque de gouvernance faible, tandis que 10 indique un risque de gouvernance élevé.